Ben J.L. Van den Branden

Showing 1-8 of 8 articles

Author Friso Kortlandt

Interventions for valvular disease

Impact of mitral valve treatment choice on mortality according to aetiology

Kortlandt F, Velu J, Schurer R, Van den Branden B, Bouma B, Kelder J, Eefting F, Swaans M, Rensing B, Baan Jr J, Van der Heyden J

April 16, 2019 | 10.4244/EIJ-D-18-00874

Author Koen Teeuwen

Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Teeuwen K, Van den Branden B, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

March 20, 2015 | 10.4244/EIJY14M08_07

Author Ben J.L. Van den Branden

Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Van den Branden B, Teeuwen K, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

November 29, 2013 | 10.4244/EIJV9I7A138

Author Koen Teeuwen

Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II)

Teeuwen K, Van den Branden B, Rahel B, Laarman G, Thijssen J, Kelder J, Slagboom T, ten Berg J, Suttorp MJ

June 28, 2013 | 10.4244/EIJV9I2A36

Author Ben J.L. Van den Branden

Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study)

Van den Branden B, Rahel B, Laarman G, Slagboom T, Kelder J, ten Berg J, Suttorp MJ

February 21, 2012 | 10.4244/EIJV7I10A190

Author Ben J.L. Van den Branden

The BioSTAR® device versus the CardioSEAL® device in patent foramen ovale closure: comparison of mid-term efficacy and safety

Van den Branden B, Luermans J, Post M, Plokker H, ten Berg J, Suttorp MJ

September 30, 2010

Author O Semeraro

Re-examining minimal luminal diameter relocation and quantitative coronary angiography - intravascular ultrasound correlations in stented saphenous vein grafts: methodological insights from the randomised RRISC trial

Semeraro O, Agostoni P, Verheye S, van Langenhove G, Van den Heuvel P, Convens C, Van den Branden B, Bruining N, Vermeersch P

March 20, 2009

Author Peter Ruygrok

One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study

Ruygrok P, Desaga M, Van den Branden B, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys P

November 20, 2007

1

Latest news

Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue

(Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right))

December 6, 2019

The challenge of innovation for the (interventional?) cardiology world

December 6, 2019

New this week: A Dose-response Meta Analysis, stroke after MitraClip and more

December 10, 2019

New update! Discover 17 new trials

(The Trials book is supported by Biotronik)

October 29, 2019

Guidance Papers

Guidelines, consensus & position papers

2019 – A leap year for valvular heart disease

(Course directors PCR London Valves 2019)

November 15, 2019

Last week's JAA's: EXTREME Study, Stent Optimization and more

December 3, 2019

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke